Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month High – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA)’s stock price reached a new 52-week high during trading on Wednesday . The stock traded as high as $99.00 and last traded at $98.99, with a volume of 2596 shares changing hands. The stock had previously closed at $98.13.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. UBS Group increased their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Finally, Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $134.30.

Oruka Therapeutics Price Performance

The firm has a market capitalization of $5.94 billion, a price-to-earnings ratio of -50.73 and a beta of -0.34. The business has a 50 day moving average of $80.19 and a 200 day moving average of $58.87.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at approximately $64,503,670.20. The trade was a 0.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares in the company, valued at approximately $2,266,703.04. The trade was a 19.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 188,406 shares of company stock valued at $12,019,683 in the last 90 days. Insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Several large investors have recently modified their holdings of ORKA. Moody Aldrich Partners LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $3,844,000. Brookwood Investment Group LLC bought a new stake in Oruka Therapeutics in the fourth quarter valued at $502,000. SG Americas Securities LLC acquired a new position in Oruka Therapeutics during the fourth quarter worth $251,000. Y Intercept Hong Kong Ltd acquired a new position in Oruka Therapeutics during the first quarter worth $1,811,000. Finally, Perceptive Advisors LLC lifted its holdings in shares of Oruka Therapeutics by 16.4% during the fourth quarter. Perceptive Advisors LLC now owns 1,476,501 shares of the company’s stock valued at $44,753,000 after acquiring an additional 208,480 shares during the period. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.